Humanigen up on trial tie-up in UK for graft-vs-host disease drug

Humanigen

11/11/2021 13:04

** Biopharmaceutical company Humanigen Inc's shares  HGEN.O 
up nearly 2% at $6.20 in premarket trading
    ** HGEN to collaborate with UK trial network on mid-to-late
stage study of lenzilumab for early treatment of acute graft
versus host disease, a condition where donor bone marrow or stem
cells attack recipient of a transplant  urn:newsml:reuters.com:*:nBw73dqJza
    ** Safety run-in component of study anticipated to be
completed in 2022
    ** U.S. FDA in Sept declined HGEN's request to give
emergency use authorisation for treatment of newly hospitalized
COVID-19 patients, saying it was unable to conclude benefits of
lenzilumab outweighed risks for use as COVID-19 treatment
 urn:newsml:reuters.com:*:nL4N2QB12Z
    ** Reviews of European and UK regulator for use of
lenzilumab in hospitalised COVID-19 patients ongoing
    ** Up to Wednesday's close, stock had slumped nearly 65%
YTD, primarily on account of U.S. FDA rejection of drug in Sept

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com;))